CY1122604T1 - Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασης - Google Patents
Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασηςInfo
- Publication number
- CY1122604T1 CY1122604T1 CY20201100026T CY201100026T CY1122604T1 CY 1122604 T1 CY1122604 T1 CY 1122604T1 CY 20201100026 T CY20201100026 T CY 20201100026T CY 201100026 T CY201100026 T CY 201100026T CY 1122604 T1 CY1122604 T1 CY 1122604T1
- Authority
- CY
- Cyprus
- Prior art keywords
- mcg
- dose
- equivalent
- angiotasin
- hypotension
- Prior art date
Links
- 208000001953 Hypotension Diseases 0.000 title 1
- 230000036543 hypotension Effects 0.000 title 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 3
- 229960002748 norepinephrine Drugs 0.000 abstract 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 3
- 150000003943 catecholamines Chemical class 0.000 abstract 2
- 102000005862 Angiotensin II Human genes 0.000 abstract 1
- 101800000733 Angiotensin-2 Proteins 0.000 abstract 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 1
- 229950006323 angiotensin ii Drugs 0.000 abstract 1
- 230000004872 arterial blood pressure Effects 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361917576P | 2013-12-18 | 2013-12-18 | |
| US201461955706P | 2014-03-19 | 2014-03-19 | |
| PCT/US2014/071186 WO2015095535A1 (en) | 2013-12-18 | 2014-12-18 | Angiotensin ii alone or in combination for the treatment of hypotension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122604T1 true CY1122604T1 (el) | 2021-03-12 |
Family
ID=53367119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100026T CY1122604T1 (el) | 2013-12-18 | 2020-01-13 | Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασης |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US9220745B2 (enExample) |
| EP (2) | EP3607962B1 (enExample) |
| JP (4) | JP6824739B2 (enExample) |
| KR (4) | KR20220028125A (enExample) |
| CN (4) | CN106061493A (enExample) |
| AU (3) | AU2014364528C1 (enExample) |
| BR (1) | BR112016013961A2 (enExample) |
| CA (1) | CA2933601A1 (enExample) |
| CY (1) | CY1122604T1 (enExample) |
| DK (2) | DK3607962T3 (enExample) |
| EA (1) | EA037823B1 (enExample) |
| ES (1) | ES2771749T3 (enExample) |
| FI (1) | FI3607962T3 (enExample) |
| HR (1) | HRP20200009T1 (enExample) |
| HU (1) | HUE047062T2 (enExample) |
| IL (1) | IL246162B (enExample) |
| LT (1) | LT2986308T (enExample) |
| MX (2) | MX380968B (enExample) |
| NZ (1) | NZ721089A (enExample) |
| PL (1) | PL2986308T3 (enExample) |
| PT (2) | PT3607962T (enExample) |
| RS (1) | RS59804B1 (enExample) |
| SI (1) | SI2986308T1 (enExample) |
| SM (1) | SMT202000018T1 (enExample) |
| WO (1) | WO2015095535A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9572856B2 (en) | 2009-12-16 | 2017-02-21 | The George Washington University a Congressionally Chartered Not-for-Profit Corporation | Method of treating low blood pressure |
| BR112016013961A2 (pt) | 2013-12-18 | 2017-10-10 | The George Washington Univ A Congressional Chartered Not For Profit Corporation | angiotensina ii sozinha ou em combinação para o tratamento da hipotensão |
| TW202214219A (zh) * | 2014-07-08 | 2022-04-16 | 美商拉荷亞製藥公司 | 治療低血壓之方法 |
| WO2016153558A1 (en) | 2015-03-20 | 2016-09-29 | Atkinson Arthur J | Use of angiotensin ii (aii) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps |
| EP3400001A1 (en) * | 2016-01-07 | 2018-11-14 | La Jolla Pharmaceutical Company | Methods of administering vasopressors |
| TW201733610A (zh) | 2016-01-07 | 2017-10-01 | 拉荷亞製藥公司 | 投與血管收縮素ｉｉ之方法 |
| WO2018191678A1 (en) * | 2017-04-14 | 2018-10-18 | La Jolla Pharmaceutical Company | Methods for administering angiotensin ii |
| US20190183962A1 (en) * | 2017-12-15 | 2019-06-20 | La Jolla Pharma, Llc | Angiotensin compositions and methods related thereto |
| WO2023244552A1 (en) * | 2022-06-15 | 2023-12-21 | Virginia Commonwealth University | Methods for fluid resuscitation of an organ donor |
| JP2025538841A (ja) * | 2022-12-12 | 2025-11-28 | プロレタリアート セラピューティクス， インコーポレイテッド | 心損傷を処置する方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU181008B (en) | 1980-01-18 | 1983-05-30 | Richter Gedeon Vegyeszet | Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position |
| US5216025A (en) * | 1989-09-13 | 1993-06-01 | Board Of Regents, The University Of Texas System | Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients |
| US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| EP1401864A1 (en) | 2001-06-04 | 2004-03-31 | Human Genome Sciences | Methods and compositions for modulating ace-2 activity |
| US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
| NO20034952D0 (no) | 2003-11-06 | 2003-11-06 | Amersham Health As | Farmasöytiske forbindelser |
| EP1699495A2 (en) | 2003-11-06 | 2006-09-13 | Amersham Health AS | Conjugates of angiotensin ii and an imaging moiety |
| FR2880807B1 (fr) * | 2005-01-19 | 2007-04-13 | Aguettant Sa Lab | Composition pharmaceutique injectable |
| WO2007040636A1 (en) | 2005-09-29 | 2007-04-12 | Fibrogen, Inc. | Methods for reducing blood pressure |
| US20090304818A1 (en) | 2005-12-30 | 2009-12-10 | May Clive N | Method of treatment |
| CA2655144A1 (en) | 2006-06-15 | 2007-12-21 | Gilead Colorado, Inc. | Antihypertensive therapy method |
| WO2008130217A1 (en) * | 2006-08-08 | 2008-10-30 | Applied Nanosystems B.V. | Cyclic angiotensin analogs |
| CN101795675A (zh) | 2006-11-17 | 2010-08-04 | 达沃尔泰拉公司 | 使用具有Eudragit包衣的Zn/果胶珠粒进行的结肠递送 |
| WO2009009907A1 (en) * | 2007-07-18 | 2009-01-22 | The University Of British Columbia | Use of vasopressin-receptor agonists for the treatment of septic shock |
| EP2161030A1 (en) * | 2008-09-09 | 2010-03-10 | Rijksuniversiteit te Groningen | Oxytocin formulations and uses thereof |
| AU2009319856A1 (en) | 2008-11-28 | 2010-06-03 | Abbvie Inc. | Stable antibody compositions and methods for stabilizing same |
| US9572856B2 (en) | 2009-12-16 | 2017-02-21 | The George Washington University a Congressionally Chartered Not-for-Profit Corporation | Method of treating low blood pressure |
| FR2959414B1 (fr) * | 2010-04-30 | 2016-01-08 | Luc Quintin | Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire |
| BR112013000744A2 (pt) | 2010-07-14 | 2020-07-14 | Cumberland Emerging Technologies, Inc | uso de um antagonista de receptor de tromboxana a2 para prevenção ou tratamento de síndrome hepatorrenal,encefalopatia hepática,e doenças associadas |
| JP6522584B2 (ja) | 2013-04-26 | 2019-05-29 | ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ | 腎不全を処置するための組成物及び方法 |
| BR112016013961A2 (pt) | 2013-12-18 | 2017-10-10 | The George Washington Univ A Congressional Chartered Not For Profit Corporation | angiotensina ii sozinha ou em combinação para o tratamento da hipotensão |
| US20150286797A1 (en) | 2014-04-02 | 2015-10-08 | David R. Ratto | System and method for administering medication |
| TW202214219A (zh) | 2014-07-08 | 2022-04-16 | 美商拉荷亞製藥公司 | 治療低血壓之方法 |
| EP3400001A1 (en) | 2016-01-07 | 2018-11-14 | La Jolla Pharmaceutical Company | Methods of administering vasopressors |
| TW201733610A (zh) | 2016-01-07 | 2017-10-01 | 拉荷亞製藥公司 | 投與血管收縮素ｉｉ之方法 |
| WO2018191678A1 (en) | 2017-04-14 | 2018-10-18 | La Jolla Pharmaceutical Company | Methods for administering angiotensin ii |
| US20190183962A1 (en) | 2017-12-15 | 2019-06-20 | La Jolla Pharma, Llc | Angiotensin compositions and methods related thereto |
-
2014
- 2014-12-18 BR BR112016013961A patent/BR112016013961A2/pt not_active Application Discontinuation
- 2014-12-18 CN CN201480075899.1A patent/CN106061493A/zh active Pending
- 2014-12-18 EA EA201691258A patent/EA037823B1/ru unknown
- 2014-12-18 ES ES14872684T patent/ES2771749T3/es active Active
- 2014-12-18 HU HUE14872684A patent/HUE047062T2/hu unknown
- 2014-12-18 EP EP19197866.7A patent/EP3607962B1/en active Active
- 2014-12-18 KR KR1020227004084A patent/KR20220028125A/ko not_active Ceased
- 2014-12-18 CN CN202010824424.5A patent/CN111920939A/zh active Pending
- 2014-12-18 LT LTEP14872684.7T patent/LT2986308T/lt unknown
- 2014-12-18 SM SM20200018T patent/SMT202000018T1/it unknown
- 2014-12-18 SI SI201431450T patent/SI2986308T1/sl unknown
- 2014-12-18 DK DK19197866.7T patent/DK3607962T3/da active
- 2014-12-18 KR KR1020247034828A patent/KR20240154702A/ko active Pending
- 2014-12-18 KR KR1020237012136A patent/KR20230051721A/ko not_active Ceased
- 2014-12-18 PT PT191978667T patent/PT3607962T/pt unknown
- 2014-12-18 CA CA2933601A patent/CA2933601A1/en active Pending
- 2014-12-18 AU AU2014364528A patent/AU2014364528C1/en active Active
- 2014-12-18 PT PT148726847T patent/PT2986308T/pt unknown
- 2014-12-18 PL PL14872684T patent/PL2986308T3/pl unknown
- 2014-12-18 NZ NZ721089A patent/NZ721089A/en unknown
- 2014-12-18 DK DK14872684.7T patent/DK2986308T3/da active
- 2014-12-18 US US14/575,127 patent/US9220745B2/en active Active
- 2014-12-18 JP JP2016539318A patent/JP6824739B2/ja active Active
- 2014-12-18 RS RS20200021A patent/RS59804B1/sr unknown
- 2014-12-18 FI FIEP19197866.7T patent/FI3607962T3/fi active
- 2014-12-18 WO PCT/US2014/071186 patent/WO2015095535A1/en not_active Ceased
- 2014-12-18 MX MX2016008108A patent/MX380968B/es unknown
- 2014-12-18 KR KR1020167019427A patent/KR102399383B1/ko active Active
- 2014-12-18 HR HRP20200009TT patent/HRP20200009T1/hr unknown
- 2014-12-18 CN CN202411722811.2A patent/CN119700926A/zh active Pending
- 2014-12-18 CN CN202011494632.XA patent/CN112546197A/zh active Pending
- 2014-12-18 EP EP14872684.7A patent/EP2986308B1/en active Active
-
2015
- 2015-11-13 US US14/941,301 patent/US10028995B2/en active Active
-
2016
- 2016-06-09 IL IL246162A patent/IL246162B/en active IP Right Grant
- 2016-06-17 MX MX2020011190A patent/MX2020011190A/es unknown
-
2018
- 2018-03-01 US US15/909,617 patent/US10493124B2/en active Active
- 2018-09-19 US US16/135,608 patent/US10765722B2/en active Active
-
2019
- 2019-04-12 US US16/382,850 patent/US11096983B2/en active Active
- 2019-08-23 JP JP2019153144A patent/JP7175506B2/ja active Active
-
2020
- 2020-01-13 CY CY20201100026T patent/CY1122604T1/el unknown
- 2020-11-26 AU AU2020277230A patent/AU2020277230A1/en not_active Abandoned
-
2021
- 2021-07-20 US US17/380,311 patent/US11559559B2/en active Active
-
2022
- 2022-07-14 JP JP2022113327A patent/JP2022137224A/ja not_active Withdrawn
-
2023
- 2023-01-23 US US18/157,933 patent/US20230226141A1/en not_active Abandoned
-
2024
- 2024-09-18 AU AU2024219851A patent/AU2024219851A1/en active Pending
-
2025
- 2025-05-09 JP JP2025078759A patent/JP2025114753A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122604T1 (el) | Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασης | |
| CY1123460T1 (el) | Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχης | |
| MX387115B (es) | Métodos para tratar la influenza. | |
| CY1122186T1 (el) | Μεθοδοι θεραπειας καρκινου | |
| CY1120506T1 (el) | Θεραπευτικα δραστικες ενωσεις και μεθοδοι χρησης αυτων | |
| MX2020001732A (es) | Tratamiento de las afecciones del sistema nervioso central. | |
| CY1124759T1 (el) | Μεθοδοι για τη θεραπεια της οξειας νεφρικης βλαβης | |
| MX385283B (es) | Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control. | |
| EA201590703A1 (ru) | Ингибиторы mek при лечении вирусных заболеваний | |
| CY1120490T1 (el) | Φαρμακο για την προληψη και/ή την θεραπευτικη αντιμετωπιση της πολυκυστικης νοσου των νεφρων | |
| EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
| BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
| EA201891968A1 (ru) | Комбинированное лечение с использованием liv1-adc и химиотерапевтического средства | |
| AR120055A1 (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal | |
| CY1123243T1 (el) | Ενωση προερχομενη απο πυραζολινη και η χρηση τησσε ενα θεραπευτικο σχημα εβδομαδιαιας δοσολογησης εναντια στην φλεγμονη και τον πονο που προερχονται απο την εκφυλιστικη ασθενεια των αρθρωσεων στα θηλαστικα | |
| EA201991688A1 (ru) | Фармацевтические комбинации для лечения рака | |
| MX2016003525A (es) | Agentes dirigidos contra una interaccion cis de molecula de orientacion repulsiva a (rgma) /neogenina o balsas lipidicas y uso de los mismos en metodos de tratamiento. | |
| EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине | |
| MX374354B (es) | Método de curación de heridas. | |
| MX373322B (es) | Tratamiento de los síntomas asociados a terapia privación de andrógenos. | |
| CY1122377T1 (el) | Αργινινη για χρηση στη θεραπεια και/ή προληψη οστεοαρθριτιδας | |
| MX2018004779A (es) | Uso terapeutico de una solucion oftalmica acuosa esteril. | |
| JOP20210347A1 (ar) | طرق لعلاج فيروس نقص المناعة البشرية | |
| CY1125036T1 (el) | Μυκητοκτονος συνθεση αποτελεσματικη κατα του μηκυτα altenaria στα εσπεριδοειδη | |
| EA202092463A1 (ru) | Ангиотензин ii самостоятельно или в комбинации для лечения гипотензии |